IGC Pharma, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $28.9M
- Price
- $0.28
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 307.1K
About
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
Quick stats
Shares outstanding103.4M
Computed float79.2M
Float / shares76.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001326205
Websitehttps://igcpharma.com
AI Summary
AI-generated1/27
standardbullishclinical trial
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026
IGC Pharma completed enrollment in its Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer's dementia, with 168 participants randomized including planned over-enrollment.
Final participant dosing is expected in early November, with topline results targeted for Q4 2026 after database lock and unblinding.
The Data Safety Monitoring Committee has recommended the trial continue without modification at each periodic review, with no treatment-related serious adverse events identified to date.
The primary endpoint is change in agitation from baseline to week six on the Cohen-Mansfield Agitation Inventory, tested across clinical sites in the United States and Canada.
Red flags
- clinical-stage company with financing needs cited as a risk factor in forward-looking statements
- topline results are a binary catalyst; Phase 2 failure risk remains